08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Downstream regulatory element antagonistic modulator (DREAM); ATP-dependent potassium channel (KATP)

Neurology INDICATION: Huntington's disease (HD) In vitro, patient sample and mouse studies suggest inhibiting DREAM with NovoNorm repaglinide could help treat HD. Striatal levels of DREAM were lower in postmortem brain tissue samples from patients...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Apeiron Biologics, Evotec deal

Evotec will use its preclinical screening technologies and assay development to evaluate small molecule modulators of downstream regulatory element antagonistic modulator (DREAM) discovered by Apeiron to treat pain. Financial terms were not disclosed. Apeiron Biologics...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; neurology; stroke Downstream regulatory element antagonistic modulator (DREAM); NMDAR (GRIN) A study in cell culture and in mice suggests that increasing DREAM signaling...